Onco-Innovations Targets Next Generation of DNA Damage Response Cancer Therapies

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development across multiple cancer indications.

The editorial noted that ONC010(TM) has demonstrated encouraging preclinical results, including extended survival and tumor growth reduction in colorectal cancer models, while the company advances manufacturing, formulation and IND-enabling activities through partnerships with Dalton Pharma Services and Nucro-Technics. Onco-Innovations also acquired Inka Health Corp., whose SynoGraph(TM) causal AI platform is designed to support patient stratification and clinical trial design as the company prepares for anticipated first-in-human studies. The report highlighted continued innovation across the biotechnology sector, citing recent regulatory and clinical milestones reported by Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD).

The DDR market’s growth underscores the importance of targeting DNA repair mechanisms in cancer therapy. By focusing on PNKP, an enzyme involved in both base excision repair and single-strand break repair, Onco-Innovations aims to exploit synthetic lethality in cancer cells with pre-existing DNA repair deficiencies. The company’s nanoparticle encapsulation technology is intended to improve drug delivery and reduce off-target effects. Preclinical data showing extended survival and tumor reduction in colorectal cancer models provides a foundation for advancing toward clinical trials.

Onco-Innovations’ acquisition of Inka Health Corp. adds a causal AI platform that could enhance patient selection and trial design, potentially accelerating development timelines and improving success rates. The company’s partnerships with Dalton Pharma Services and Nucro-Technics for manufacturing and IND-enabling activities indicate a strategic approach to moving ONC010 toward clinical testing.

The broader biotechnology sector continues to see innovation in DDR therapies, with major pharmaceutical companies like Merck, Pfizer, GSK, and Gilead reporting recent regulatory and clinical milestones. This landscape highlights the competitive yet promising nature of the field. Onco-Innovations’ focus on a novel target and delivery system could differentiate it from existing therapies if clinical data prove favorable.

For more information, see the full press release at https://ibn.fm/cFCop and the company’s newsroom at https://ibn.fm/ONNVF.